These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 22883664)

  • 21. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of HER2 protein examination in ductal carcinoma in situ.
    Horimoto Y; Tokuda E; Arakawa A; Kosaka T; Saito M; Kasumi F
    J Surg Res; 2011 May; 167(2):e205-10. PubMed ID: 20018297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Luminal B breast tumors are not HER2 positive.
    Bhargava R; Dabbs DJ
    Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract]   [Full Text] [Related]  

  • 24. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
    Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma.
    Hicks DG; Whitney-Miller CL
    Biotech Histochem; 2013 May; 88(3-4):121-31. PubMed ID: 23293935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
    Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
    Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How is Her-2/neu status established when Her-2/neu and chromosome 17 centromere are both amplified?
    Press MF
    Am J Clin Pathol; 2006 Nov; 126(5):673-4. PubMed ID: 17050063
    [No Abstract]   [Full Text] [Related]  

  • 28. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
    Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
    Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.
    Pu X; Shi J; Li Z; Feng A; Ye Q
    Pathol Res Pract; 2015 Jun; 211(6):421-5. PubMed ID: 25818873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. c-erbB-2 oncogene in breast cancer: the right target or a decoy?
    Anderson TJ
    Hum Pathol; 1992 Sep; 23(9):971-3. PubMed ID: 1355463
    [No Abstract]   [Full Text] [Related]  

  • 32. Some DCIS is different molecularly from DCIS with co-existing IDC.
    Steinman S; Bourne P; Yang Q; Tang P; Wang J
    Breast J; 2008; 14(1):122-3. PubMed ID: 18186882
    [No Abstract]   [Full Text] [Related]  

  • 33. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"): a simulator of normal mammary epithelium.
    Moinfar F; Man YG; Bratthauer GL; Ratschek M; Tavassoli FA
    Cancer; 2000 May; 88(9):2072-81. PubMed ID: 10813719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?
    Tubbs RR; Stoler MH
    Mod Pathol; 2000 Jan; 13(1):1-3. PubMed ID: 10658903
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
    Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance.
    Lambein K; Van Bockstal M; Vandemaele L; Geenen S; Rottiers I; Nuyts A; Matthys B; Praet M; Denys H; Libbrecht L
    Am J Clin Pathol; 2013 Oct; 140(4):561-6. PubMed ID: 24045554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letter.
    Moelans CB; de Weger RA; van Diest PJ
    Clin Cancer Res; 2010 Dec; 16(24):6177; author reply 6178. PubMed ID: 21169261
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section.
    Reisenbichler ES; Horton D; Rasco M; Andea A; Hameed O
    Am J Clin Pathol; 2012 Jan; 137(1):102-10. PubMed ID: 22180483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER2 assessment by silver in situ hybridization: where are we now?
    Sanguedolce F; Bufo P
    Expert Rev Mol Diagn; 2015 Mar; 15(3):385-98. PubMed ID: 25578771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.